Xianling Gubao Capsule Prevents Cadmium-Induced Kidney Injury.
Xianling Gubao Capsule (XGC), a kind of capsule preparation of Chinese herbal officially approved for sale by the National Medical Products Administration (NMPA), has the effect of tonifying kidney and strengthening bones. Although the impact of XGC in treating bone diseases has been widely studied,...
| Publicado en: | BioMed Research International pp. 1 - 10 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
9/28/2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=152681254&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 152681254 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 9/28/2021 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 152681254 152681254 152681254 10.1155/2021/3931750 152681254 ppf: 1 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Xianling Gubao Capsule Prevents Cadmium-Induced Kidney Injury. aug: au: Huang, Jian Ma, Xiao-tong Xu, Duo-duo Yao, Bao-jin Zhao, Da-qing Leng, Xiang-yang Liu, Jia affil: Department of Pharmaceutical Science, Changchun University of Chinese Medicine, Changchun, China sug: subj: Kidney Diseases Prevention and Control Drugs, Chinese Herbal Therapeutic Use Cadmium Adverse Effects Medicine, Chinese Traditional Capsules Therapeutic Use Animal Studies Mice Administration, Intraperitoneal Blood Urea Nitrogen Evaluation Creatinine Blood Immunohistochemistry Polymerase Chain Reaction Proteins Metabolism RNA, Messenger Metabolism Necrosis Prevention and Control Descriptive Statistics ab: Xianling Gubao Capsule (XGC), a kind of capsule preparation of Chinese herbal officially approved for sale by the National Medical Products Administration (NMPA), has the effect of tonifying kidney and strengthening bones. Although the impact of XGC in treating bone diseases has been widely studied, the effect of XGC in kidney injury is unknown yet. The kidney injury model is established by intraperitoneal injection with cadmium chloride (CdCl2). Before model establishment, each XGC group was pregavaged with XGC for 10 d. After 10 d, CdCl2 was injected intraperitoneally into the model group and each XGC group, each XGC group continued to be gavaged with XGC for 4 weeks, and the control group was gavaged with equal doses of distilled water once daily. The level of serum urea nitrogen (BUN) and serum creatinine (Cr) is evaluated by kit. The effect of XGC on protecting kidney injury in mice with kidney injury is analyzed by histopathology (HE stain), immunohistochemistry (IHC), and real-time fluorescence quantitative PCR (RT-qPCR). The results show that CdCl2 significantly increases the level BUN and Cr in serum and results in remarkable pathological changes in the nephron, including tubule edema, congestion, and necrosis. While oral administration of XGC can significantly decrease BUN and Cr in serum and prevent and protect the kidney from the above injuries. In addition, the protein expression of p-mTOR was remarkably reduced, and the ratio of LC3II/LC3I protein and mRNA was significantly increased in mice with oral administration of XGC. Our findings suggest that XGC can prevent and protect kidney injury by improving the state of renal tubular hyperemia and necrosis and reduce the level of BUN and Cr in cadmium poisoning mice. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|